ADHD Meds May Lower Suicide Risk

The risk spike happens before treatment starts — and falls with medication

STUDY: Adams SM et al, Biological Psychiatry: Global Open Science 2026;6:100698

STUDY TYPE: Within-individual observational study

FUNDING: American Foundation for Suicide Prevention; Indiana University; Swedish Research Council

Background

People with ADHD are more than twice as likely to attempt suicide and six times more likely to die by suicide compared to those without ADHD. The question is whether the medications used to treat ADHD raise or lower that risk.

The Study

Using U.S. insurance claims data from 2016 to 2021, researchers followed 830,352 people ages 9–64 with ADHD who filled at least one prescription for a stimulant, atomoxetine, or an alpha-2 agonist (guanfacine or clonidine). A within-individual design compared each person’s suicidal behavior rate — defined as emergency visits or hospitalizations for suicide attempts or self-harm — during treatment versus off-treatment periods.

Risk was most elevated in the two months before treatment started: odds of suicidal behavior were 50% higher before stimulants, 163% higher before atomoxetine, and 199% higher before alpha-2 agonists, compared to other off-treatment periods. During active treatment, odds were modestly elevated compared to stable off-treatment baseline — 11% higher for stimulants, 17% for atomoxetine, 31% for alpha-2 agonists. But when on-treatment periods were compared directly to the high-risk pretreatment window, all three medication classes looked protective.

Findings were consistent across sex and race-ethnicity. One exception: stimulants were associated with 28% lower odds of suicidal behavior in adults ages 46–64, a pattern not seen in younger groups.

Practice Implications

The study provides reassurance, suggesting ADHD meds do not cause, and may help prevent, suicide.